Arzneimitteltherapie in der Schwangerschaft

Der Gastroenterologe - Tập 11 - Trang 323-333 - 2016
A. Blank1, A. Eidam1, A. Lampert1,2, A. Pathil-Warth3, G. Mikus1
1Abteilung Klinische Pharmakologie & Pharmakoepidemiologie, UniversitätsKlinikum Heidelberg – Medizinische Klinik, Heidelberg, Deutschland
2Kooperationseinheit Klinische Pharmazie, Universität Heidelberg, Heidelberg, Deutschland
3Abteilung Gastroenterologie und Infektionskrankheiten, Universitätsklinikum Heidelberg – Medizinische Klinik, Heidelberg, Deutschland

Tóm tắt

Arzneimittel für schwangere Frauen können durch Therapie von Erkrankungen großen Nutzen, aber auch Gefahren durch Toxizität auf Entwicklungsprozesse mit sich bringen. Eine Nutzen-Risiko-Analyse muss die Aspekte der mütterlichen und kindlichen Seite betrachten und abwägen. Die Datenlage ist dabei oft nicht ausreichend und weitere klinische Studien wären notwendig, um das Gefährdungspotenzial mancher Substanzen besser definieren zu können. Die Mehrzahl der Frauen nimmt im Verlauf einer Schwangerschaft Arzneimittel und damit potenzielle Noxen ein. Es ist deshalb wichtig, Einflussfaktoren auf die Variabilität zu berücksichtigen und v. a. die Exposition von schädigenden Substanzen im ersten Trimenon zu vermeiden. Notwendige Verschreibungen außerhalb der Zulassung müssen den Patientinnen erklärt und dokumentiert werden. Das pränataltoxikologische Risiko medikamentöser Therapieansätze für ausgewählte gastroenterologische Symptome und Krankheitsbilder wird in Grundzügen beschrieben.

Tài liệu tham khảo

Botting J (2002) The History of Thalidomide. Drug news. Perspectives (Montclair) 15:604–611

Klein J, Charach R, Sheiner E (2015) Treating diabetes during pregnancy. Expert Opin Pharmacother 16:357–368

Smolina K, Hanley GE, Mintzes B et al (2015) Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002–2011: A Population-Based Cohort Study. PLoS ONE 10:e0128312

Crespin S, Bourrel R, Hurault-Delarue C et al (2011) Drug prescribing before and during pregnancy in south west France: a retrolective study. Drug Saf 34:595–604

Irvine L, Flynn RW, Libby G et al (2010) Drugs dispensed in primary care during pregnancy: a record-linkage analysis in Tayside. Scotland Drug Saf 33:593–604

Mccarthy M (2015) Use of prescription drugs is common during pregnancy, US study finds. BMJ 351:h4421

Baylis F (2010) Pregnant women deserve better. Nature 465:689–690

Matsui D, Koren G (2015) Creating a new ethical climate for drug research in children and pregnant women. Paediatr Drugs 17:1–3

Matsui D (2015) Ethics of studies of drugs in pregnancy. Paediatr Drugs 17:31–35

Charlton RA, Neville AJ, Jordan S et al (2014) Healthcare databases in Europe for studying medicine use and safety during pregnancy. Pharmacoepidemiol Drug Saf 23:586–594

De Jonge L, Garne E, Gini R et al (2015) Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study. Drug Saf 38:1083–1093

Friedman JM (2010) The principles of teratology: are they still true? Birth defects research. Part A Clin Mol Teratol 88:766–768

Wilson J (1977) Current status of teratology: general principles and mechanisms derived from animal studies. In: Wilson J, Fraser F (Hrsg) Handbook of teratology. Plenum Press, New York, S 47–74

Feghali M, Venkataramanan R, Caritis S (2015) Pharmacokinetics of drugs in pregnancy. Semin Perinatol 39:512–519

Loebstein R, Lalkin A, Koren G (1997) Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 33:328–343

Pavek P, Ceckova M, Staud F (2009) Variation of drug kinetics in pregnancy. Curr Drug Metab 10:520–529

Zhao Y, Hebert MF, Venkataramanan R (2014) Basic obstetric pharmacology. Semin Perinatol 38:475–486

Fantasia HC, Harris AL (2015) Changes to Pregnancy and Lactation Risk Labeling for Prescription Drugs. Nurs Womens Health 19:266–270

Ramoz LL, Patel-Shori NM (2014) Recent changes in pregnancy and lactation labeling: retirement of risk categories. Pharmacotherapy 34:389–395

Fachinfo-Service® Fachinformationsverzeichnis Deutschland. www.fachinfo.de. Zugegriffen: 31. Mai 2016

Embryotox. http://www.embryotox.de. Zugegriffen: 31. Mai 2016

Schaefer C, Weber-Schöndorfer C, Borisch C et al (2015) www.embryotox.de. In:Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie, Berlin

Grezy-Chabardes C, Fournier JP, Dupouy J et al (2015) Patients’ Knowledge About Analgesic-Antipyretic Medications Purchased in Community Pharmacies: A Descriptive Study. J Pain Palliat Care Pharmacother 29:334–340

Anonymous (2015) Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. Obstet Gynecol 126:e12–24

Boregowda G, Shehata HA (2013) Gastrointestinal and liver disease in pregnancy. Best practice & research. Clin Obstet Gynaecol 27:835–853

Anonymous (2009) Antiemetische Therapie bei Schwangerschaftserbrechen. arznei-telegramm 40:8789

Schaefer C, Spielmann H, Vetter K et al (2012) Arzneimittel in Schwangerschaft und Stillzeit. Elsevier GmbH, Urban Fischer Verlag, München

Ding M, Leach M, Bradley H (2013) The effectiveness and safety of ginger for pregnancy-induced nausea and vomiting: a systematic review. Women Birth 26:e26–30

Giacosa A, Morazzoni P, Bombardelli E et al (2015) Can nausea and vomiting be treated with ginger extract? Eur Rev Med Pharmacol Sci 19:1291–1296

Matok I, Gorodischer R, Koren G et al (2010) The safety of H(2)-blockers use during pregnancy. J Clin Pharmacol 50:81–87

Matok I, Levy A, Wiznitzer A et al (2012) The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 57:699–705

Gill SK, O’brien L, Einarson TR et al (2009) The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 104:1541–1545

Majithia R, Johnson DA (2012) Are proton pump inhibitors safe during pregnancy and lactation? Evidence to date. Drugs 72:171–179

Pasternak B, Hviid A (2010) Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 363:2114–2123

Li BZ, Threapleton DE, Wang JY et al (2015) Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ 351:h4052

Thung I, Aramin H, Vavinskaya V et al (2016) Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 43:514–533

Fischbach W, Malfertheiner P, Lynen JP et al (2016) k‑Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Awmf Regist 021(007):2

Cardaropoli S, Rolfo A, Todros T (2014) Helicobacter pylori and pregnancy-related disorders. World J Gastroenterol : Wjg 20:654–664

Diav-Citrin O, Shechtman S, Gotteiner T et al (2001) Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 63:186–192

Bradley CS, Kennedy CM, Turcea AM et al (2007) Constipation in pregnancy: prevalence, symptoms, and risk factors. Obstet Gynecol 110:1351–1357

Trottier M, Erebara A, Bozzo P (2012) Treating constipation during pregnancy. Can Fam Physician 58:836–838

Hoffmann JC, Preiss JC, Autschbach F et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46:1094–1146

Huang VW, Habal FM (2014) From conception to delivery: managing the pregnant inflammatory bowel disease patient. World J Gastroenterol : Wjg 20:3495–3506

Rahimi R, Nikfar S, Rezaie A et al (2008) Pregnancy outcome in women with inflammatory bowel disease following exposure to 5‑aminosalicylic acid drugs: a meta-analysis. Reproductive Toxicol 25:271–275

Schulze H, Esters P, Dignass A (2014) Review article: the management of Crohn’s disease and ulcerative colitis during pregnancy and lactation. Aliment Pharmacol Ther 40:991–1008

Coelho J, Beaugerie L, Colombel JF et al (2011) Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 60:198–203

Damas OM, Deshpande AR, Avalos DJ et al (2015) The Issues We Face Today. Journal of Crohn’s & colitis. Treat Inflamm Bowel Dis Pregnancy 9:928–936

Khan N, Asim H, Lichtenstein GR (2014) Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf 13:1699–1708

Han GR, Xu CL, Zhao W et al (2012) Management of chronic hepatitis B in pregnancy. World J Gastroenterol : Wjg 18:4517–4521

He T, Jia J (2016) Chronic HBV: which pregnant women should be treated? Liver Int 36(Suppl 1):105–108

Dionne-Odom J, Tita AT et al. (2016) #38: Hepatitis B in pregnancy screening, treatment, and prevention of vertical transmission. Am J Obstet Gynecol 214(1):6–14

Brown RS (2016) Jr., Mcmahon BJ, Lok AS et al. Antivir Ther Chronic Hepat B Viral Infect Dur Pregnancy: A Syst Rev Meta-analysis Hepatol 63:319–333

Wang L, Kourtis AP, Ellington S et al (2013) Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clin Infect Dis 57:1773–1781

Thông tin
Thông tin xuất bản

Der Gastroenterologe

Tập 11

323-333

Thông tin tác giả